PRKAA1 and neoplasm: Activated AMPK phosphorylates the tuberous sclerosis complex (an inhibitor of mammalian target of rapamycin (mTOR)), leading to the up regulation of its activity and subsequent mTOR inhibition and tumor suppression [44].